Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers

Area of Science:

• Oncology
• Gynecologic Oncology
• Molecular Biology

Background:

• HER2-targeting therapies are established in breast, gastric, and lung cancers.
• Emerging data indicate a significant role for HER2-targeted treatments in gynecologic malignancies.
• HER2 overexpression is prevalent across various gynecologic cancers, including endometrial, ovarian, cervical, and vulvar types.

Purpose of the Study:

• To review the evidence supporting HER2-targeted therapies in gynecologic cancers.
• To highlight the rationale for using HER2-directed treatments in these malignancies.
• To discuss potential therapeutic strategies and the importance of understanding resistance mechanisms.

Main Methods:

• Review of accumulating data on HER2 expression and targeted therapies in gynecologic cancers.
• Analysis of varied methodologies for HER2 testing in these patient populations.
• Exploration of different classes of HER2-targeted agents, including TKIs, ADCs, and ISACs.

Main Results:

• Substantial proportions of endometrial, ovarian, cervical, and vulvar cancers overexpress HER2.
• Evidence supports the efficacy of HER2-targeted therapies in these gynecologic malignancies.
• Various HER2-targeting agents, such as tyrosine kinase inhibitors and antibody-drug conjugates, are relevant.

Conclusions:

• HER2-targeted therapies represent a rational approach for managing HER2-overexpressing gynecologic cancers.
• Understanding resistance mechanisms is crucial for developing effective combinatorial strategies.
• Further investigation is warranted to optimize HER2-directed treatment paradigms in gynecologic oncology.